RT Journal Article
SR Electronic
T1 Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.17.22276537
DO 10.1101/2022.06.17.22276537
A1 Wilcox, Naomi
A1 Dumont, Martine
A1 González-Neira, Anna
A1 Carvalho, Sara
A1 Beauparlant, Charles Joly
A1 Crotti, Marco
A1 Luccarini, Craig
A1 Soucy, Penny
A1 Dubois, Stéphane
A1 Nuñez-Torres, Rocio
A1 Pita, Guillermo
A1 Alonso, M. Rosario
A1 Álvarez, Nuria
A1 Baynes, Caroline
A1 Becher, Heiko
A1 Behrens, Sabine
A1 Bolla, Manjeet K.
A1 Castelao, Jose E.
A1 Chang-Claude, Jenny
A1 Cornelissen, Sten
A1 Dennis, Joe
A1 Dörk, Thilo
A1 Engel, Christoph
A1 Gago-Dominguez, Manuela
A1 Guénel, Pascal
A1 Hadjisavvas, Andreas
A1 Hahnen, Eric
A1 Hartman, Mikael
A1 Herráez, Belén
A1 SGBCC Investigators
A1 Jung, Audrey
A1 Keeman, Renske
A1 Kiechle, Marion
A1 Li, Jingmei
A1 Loizidou, Maria A.
A1 Lush, Michael
A1 Michailidou, Kyriaki
A1 Panayiotidis, Mihalis I.
A1 Sim, Xueling
A1 Teo, Soo Hwang
A1 Tyrer, Jonathan P.
A1 van der Kolk, Lizet E.
A1 Wahlström, Cecilia
A1 Wang, Qin
A1 Benitez, Javier
A1 Schmidt, Marjanka K.
A1 Schmutzler, Rita K.
A1 Pharoah, Paul D.P.
A1 Droit, Arnaud
A1 Dunning, Alison M.
A1 Kvist, Anders
A1 Devilee, Peter
A1 Easton, Douglas F.
A1 Simard, Jacques
YR 2022
UL http://medrxiv.org/content/early/2022/06/17/2022.06.17.22276537.abstract
AB Linkage and candidate gene studies have identified several breast cancer susceptibility genes, but the overall contribution of coding variation to breast cancer is unclear. To evaluate the role of rare coding variants more comprehensively, we performed a meta-analysis across three large whole-exome sequencing datasets, containing 16,498 cases and 182,142 controls. Burden tests were performed for protein-truncating and rare missense variants in 16,562 and 18,681 genes respectively. Associations between protein-truncating variants and breast cancer were identified for 7 genes at exome-wide significance (P<2.5×10-6): the five known susceptibility genes BRCA1, BRCA2, CHEK2, PALB2 and ATM, together with novel associations for ATRIP and MAP3K1. Predicted deleterious rare missense or protein-truncating variants were additionally associated at P<2.5×10-6 for SAMHD1. The overall contribution of coding variants in genes beyond the previously known genes is estimated to be small.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by grants from: Genome Canada Genome Quebec Canadian Institutes of Health Research European Union Horizon 2020 Research and Innovation Programme Wellcome TrustAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A list of ethics committees is provided as a separate supplementary table.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from UK Biobank are available through application to UK Biobank. Data from the Breast Cancer Association Consortium (BCAC) used in the present study are available upon reasonable request through the BCAC Data Access Co-ordinating Committee.